Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 10 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Breast Neoplasms 2 Salivary Gland Neoplasms 1 Prostate Cancer Non-Metastatic 1 Non-metastatic Prostate Cancer 1 Neoplasms 1 Healthy Volunteers 1 Carcinoma, Non-Small-Cell Lung 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Female 1 Biochemically Recurrent Prostate Cancer 1 Advanced Prostate Carcinoma 1

Interventions

Gemcitabine 109 Paclitaxel 92 Carboplatin 79 Bevacizumab 75 pembrolizumab 74 Surveys and Questionnaires 70 Docetaxel 69 Cisplatin 67 Nivolumab 48 Exercise 48 Capecitabine 48 Cyclophosphamide 47 Sorafenib 43 Fluorouracil 43 Irinotecan 42 Pemetrexed 37 Albumin-Bound Paclitaxel 35 Radiotherapy 34 Dexamethasone 34 Blood Specimen Collection 34 Oxaliplatin 31 Leucovorin 31 Erlotinib Hydrochloride 31 trametinib 30 130-nm albumin-bound paclitaxel 29 Cetuximab 28 Therapeutics 26 Ipilimumab 26 Standard of Care 25 Methods 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms × darolutamide × Clear all

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡